Pharmacokinetics / pharmacodynamics as a step towards therapy...
PK/PD parameters: a first sight
What does the clinician (and the patient) want ?
Pharmacokinetics ...
Pharmacodynamics ...
Pharmacokinetic/ Pharmacodynamics in Drug Development and Evaluation of Efficacy (1/2)
PK/PD in drug develop-ment A view from FDA
Pharmacokinetic/ Pharmacodynamics in Drug Development and Evaluation of Efficacy (2/2)
Pharmacokinetic/ Pharmacodynamics and antibiotic resistance...
PK/PD and drug devlop-ment A view from EMEA
Pharmacokinetic/ Pharmacodynamics in Drug Development and Evaluation
Pharmacokinetic / Pharmacodynamic parameters: a 2d sight
PK/PD: role of concentration
PK/PD: role of concentration an example with Listeria monocytogenes
PK/PD: role of time
PK/PD of FQ: in vitro dynamic models
PK/PD of fluoroquinolones: role of the 24h-AUC MIC ciprofloxacin in hospital-acquired pneumonia
How do you get a given 24h-AUC ? 1. importance of the dose (a)
How do you get a given 24h-AUC ? 1. importance of the dose (b)
How do you get a given 24h-AUC ? 1. importance of the dose (c)
How do you get a given 24h-AUC ? 2. importance of the clearance
Can you use 24h-AUC / MIC to optimize your therapy ?
24h-AUC / MIC as a tool to determine acceptable sensitivities to fluoroquinolones (p.o.)
Is 24h-AUC / MIC the only critical parameter ?
The role of the peak : animal models
Fq PK/PD : peak to MIC ratio in the clinic (1/2)
Fq PK/PD : peak to MIC ratio in the clinic (2/2)
Peak concentrations of the main fluoroquinolones (p.o.)
Peak concentrations as a tool to determine acceptable sensitivities to fluoroquinolones (p.o.)
PK/PD : what do we need to do ?
Peak concentrations and 24h-AUC / MIC as predictors of efficacy...
But isn’t anything more about the peak ?
Could efficacy prevent the emergence of resistance ?
The importance of double mutation ...
Mutant-prevention concentration (MPC) (1/3)
Bactericidal activity of FQs against M. bovis
Mutant-prevention concentration (MPC) (2/3) ...
Role of the C8-methoxy in decreasing MPC
N-1-cyclopropyl-fluoroquinolones with a C8-methoxy
Peak concentrations as a tool to prevent emergence of resistance (MPC): accepting NCCLS breakpoints ...
Peak concentrations as a tool to prevent emergence of resistance (MPC): using “ PK / PD acceptable ” MICs
The design of the SUPERFLOXACIN... Pharmacokinetics / Pharmacodynamics...
A new fluoroquinolone for the year 2,000
Pharmacokinetics / Pharmacodynamics Will this really help ?
And we may have a very bright future...
Email: tulkens@facm.ucl.ac.be
Home Page: http://www.md.ucl.ac.be/facm/facm-conferences.htm